Recombinant human interferon α2a injection

Pharmacology: Recombinant human interferon alpha; 2a has broad-spectrum antiviral, anti-tumor and immunomodulatory functions. Interferon binds to cell surface receptors, induces cells to produce a variety of antiviral proteins, inhibits virus reproduction in cells, and improves immune function, including enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells. Toxicology: Acute toxicity test: The maximum dose was injected intravenously or intramuscularly into mice, all of them survived, no death, and the LD50 was not measured. Long-term toxicity test: Rats were given the drug continuously for one month, and all animals survived without abnormal reactions.

Main ingredients: Ingredients: Active ingredients: recombinant human interferon alpha; 2a; Inactive ingredients: sodium chloride, Tween 80, sodium citrate, citric acid, methyl parahydroxybenzoate, water for injection.

Colorless, transparent, clear liquid with no insoluble matter visible to the naked eye.

It can be used to treat acute and chronic viral hepatitis (type B, type C, etc.), genital warts, hairy cell leukemia, chronic myeloid leukemia, lymphoma, AIDS-related Kaposi's sarcoma, malignant melanoma and other diseases.

This product can be injected intramuscularly, subcutaneously and intralesionally. 1. Chronic hepatitis B: The recommended dose is 3 to 5 million international units (IU) each time, injected once a day or every other day. A course of treatment is 3 to 6 months, and the doctor can adjust the dose according to the specific situation of the patient. 2. Chronic hepatitis C: The recommended dose is 3 to 5 million international units (IU) each time, injected once a day or every other day. A course of treatment is 3 to 6 months, and the doctor can adjust the dose according to the specific situation of the patient. 3. Genital warts: The recommended dose is 1 to 3 million international units (IU) each time, injected three times every other day per week. A course of treatment is 1 to 2 months. 4. Hairy cell leukemia: The recommended dose is 3 million international units (IU) each time, injected three times every other day per week, and the doctor can adjust the dose according to the specific situation of the patient. Usually, the effect is shown after 1 to 2 months of treatment, and intermittent treatment can be carried out afterwards to achieve long-term remission of the disease. 5. Chronic myeloid leukemia: The recommended dose is 3 to 9 million international units (IU) per day for three months. The doctor can adjust the dose according to the patient's specific situation. After the blood picture is relieved, maintenance treatment can be carried out, with injections every other day. Cytogenetic indicators can be relieved after 9 to 10 months.

The most common adverse reactions to this product are fever, chills, fatigue, headache, muscle aches, anorexia and other flu-like symptoms. Taking antipyretic analgesics (paracetamol, etc.) can alleviate or eliminate these symptoms, and these symptoms can also be alleviated with continued medication or dosage adjustments. Common hematological abnormalities include leukopenia, thrombocytopenia and increased transaminase.

Patients with a history of allergy to interferon α2b or other ingredients of this preparation, as well as patients with severe liver, kidney and bone marrow dysfunction should not use this product.

Precautions for children: It is not clear. Precautions for pregnancy and lactation: Although animal experiments have not shown that recombinant human interferon α2a has teratogenic effects, its harm to human embryos cannot be ruled out. When recombinant human interferon α2a was used in early to mid-pregnancy rhesus monkeys at doses far exceeding clinical doses, it was observed that recombinant human interferon α2a had an abortion effect. It is not clear whether recombinant human interferon α2a can be secreted in human milk, so whether to terminate breastfeeding or medication should be decided based on the importance of the mother. Precautions for the elderly: It is not clear.

Recombinant human interferon alpha;2a may affect the oxidative metabolism process by reducing the activity of intrahepatic microsomal cytochrome P450. Reports have confirmed that the clearance of theophylline in the body decreases after starting to use recombinant human interferon alpha;2a. Neurotoxicity, hematotoxicity, and cardiac toxicity caused by drugs taken previously or recently will increase due to the use of recombinant human interferon alpha;2a. Interactions will occur when used in combination with drugs with central effects.

This product should be stored at 2-8°C, away from light, and do not freeze.

5 million IU

24 months

Shenyang Sunshine Pharmaceutical Co., Ltd.

• Founded in:

  1993-01-03

• Address:

  No. 3, 1A, No. 10 Road, Shenyang Economic and Technological Development Zone

• Tax NO.:

  9121010660460338X6

• Registered Funds:

  1,000,000,000 Yuan

• Website:

  Log in to view

• Email:

  Log in to view